Spyre Therapeutics, Inc. Common Stock SYRE
i
Market datapartial · fetched 2026-11-12T02:56:40.126Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:39:26.448642447Z
FundamentalsAlpha Vantage · unavailable
Spyre Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 130.58 | 130.4% | 23.2% | 93.76 | 120.9% | 15.3% |
| 25Δ | 122.55 | 107.3% | 15.9% | 98.89 | 92.5% | 10.6% |
| 30Δ | 116.62 | 83.2% | 10.4% | 101.71 | 78.9% | 8.1% |
| 35Δ | 113.64 | 72.1% | 7.9% | 103.93 | 69.3% | 6.3% |
| 40Δ | 111.61 | 65.9% | 6.3% | 105.76 | 65.5% | 5.1% |
| 45Δ | 109.74 | 60.8% | 4.9% | 107.20 | 67.1% | 4.5% |
| 50Δ | 108.46 | 60.3% | 4.2% | 108.65 | 68.8% | 4.0% |
| 55Δ | 107.17 | 59.7% | 3.6% | 110.12 | 70.5% | 3.4% |
| 60Δ | 105.89 | 59.2% | 3.0% | 112.00 | 72.8% | 3.0% |
| 65Δ | 104.60 | 58.4% | 2.4% | 113.87 | 75.2% | 2.5% |
| 70Δ | 103.30 | 57.2% | 2.0% | 116.01 | 77.5% | 2.1% |
| 75Δ | 102.00 | 55.9% | 1.6% | 118.52 | 79.7% | 1.7% |
| 80Δ | 100.70 | 54.6% | 1.1% | 121.73 | 83.5% | 1.3% |
20Δ
- Pseudo strike
- 130.58
- IV
- 130.4%
- B/E move
- 23.2%
- Pseudo strike
- 93.76
- IV
- 120.9%
- B/E move
- 15.3%
25Δ
- Pseudo strike
- 122.55
- IV
- 107.3%
- B/E move
- 15.9%
- Pseudo strike
- 98.89
- IV
- 92.5%
- B/E move
- 10.6%
30Δ
- Pseudo strike
- 116.62
- IV
- 83.2%
- B/E move
- 10.4%
- Pseudo strike
- 101.71
- IV
- 78.9%
- B/E move
- 8.1%
35Δ
- Pseudo strike
- 113.64
- IV
- 72.1%
- B/E move
- 7.9%
- Pseudo strike
- 103.93
- IV
- 69.3%
- B/E move
- 6.3%
40Δ
- Pseudo strike
- 111.61
- IV
- 65.9%
- B/E move
- 6.3%
- Pseudo strike
- 105.76
- IV
- 65.5%
- B/E move
- 5.1%
45Δ
- Pseudo strike
- 109.74
- IV
- 60.8%
- B/E move
- 4.9%
- Pseudo strike
- 107.20
- IV
- 67.1%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 108.46
- IV
- 60.3%
- B/E move
- 4.2%
- Pseudo strike
- 108.65
- IV
- 68.8%
- B/E move
- 4.0%
55Δ
- Pseudo strike
- 107.17
- IV
- 59.7%
- B/E move
- 3.6%
- Pseudo strike
- 110.12
- IV
- 70.5%
- B/E move
- 3.4%
60Δ
- Pseudo strike
- 105.89
- IV
- 59.2%
- B/E move
- 3.0%
- Pseudo strike
- 112.00
- IV
- 72.8%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 104.60
- IV
- 58.4%
- B/E move
- 2.4%
- Pseudo strike
- 113.87
- IV
- 75.2%
- B/E move
- 2.5%
70Δ
- Pseudo strike
- 103.30
- IV
- 57.2%
- B/E move
- 2.0%
- Pseudo strike
- 116.01
- IV
- 77.5%
- B/E move
- 2.1%
75Δ
- Pseudo strike
- 102.00
- IV
- 55.9%
- B/E move
- 1.6%
- Pseudo strike
- 118.52
- IV
- 79.7%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 100.70
- IV
- 54.6%
- B/E move
- 1.1%
- Pseudo strike
- 121.73
- IV
- 83.5%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.95% | |
| 67.88% | |
| 67.47% | |
| 69.31% | |
| 68.15% | |
| 69.25% | |
| 68.48% | |
| 68.48% | |
| 68.95% | |
| 70.80% |
Biotechnology
TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions.…
More →TECH
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is…
More →TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →TENX
Description unavailable
More →TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →